<DOC>
	<DOCNO>NCT00935662</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability AZD8329 give single dose increase dose strength , also identify high tolerate dose future study .</brief_summary>
	<brief_title>A First Time Man , Study Assess Safety AZD8329 After Single Ascending Oral Doses</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Have body mass index 19 30 kg/m2 weigh least 50 kg Any clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result study , subjectÂ´s ability participate Any clinically significant abnormality clinical chemistry , haematology urinalysis result judge investigator Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>First time man</keyword>
	<keyword>Safety study</keyword>
	<keyword>AZD8329</keyword>
</DOC>